To define the impact of CMV viral load on CMV disease, overall mortality (OM), and nonrelapse mortality (NRM) in patients undergoing hematopoietic cell transplantation (HCT), particularly in light of recent advancements in transplantation techniques.
Key Findings:
76% of patients experienced CMV reactivation by day 100 post-HCT, with lower incidence in young children, indicating a need for tailored monitoring strategies.
CMV reactivation was associated with a 6.8 times higher risk of CMV disease, underscoring the critical need for vigilant monitoring.
CMV viral load >3 log10 and lymphocyte count <300 cells/μL correlated strongly with increased mortality, highlighting the importance of these metrics in patient management.
Interpretation:
CMV viral load remains a significant predictor of CMV disease and mortality outcomes in HCT patients, although the association with overall and nonrelapse mortality has diminished with improved transplantation techniques, necessitating ongoing vigilance in monitoring.
Limitations:
Study relies on retrospective data, which may introduce biases, particularly in patient selection and outcome assessment.
Lack of data on viral load endpoints in pediatric populations compared to adults, which may limit the generalizability of findings.
Conclusion:
Despite advancements in transplantation techniques reducing mortality, CMV viral load continues to be a critical factor in predicting adverse outcomes in HCT recipients, emphasizing the need for ongoing monitoring and management strategies.
by Alicja Sadowska-Klasa, Hu Xie, Danniel Zamora, Alpana Waghmare, Joshua A Hill, Elizabeth R Duke, Margaret L Green, Masumi Ueda Oshima, Brenda M Sandmaier, Keith R Jerome, Wendy M Leisenring, Michael Boeckh
